MVASI™ is a vascular endothelial growth factor inhibitor indicated for the treatment of: MVASI™, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer... Read More
The MAPLE trial: a large comparative clinical study (N = 642) that demonstrated the clinical similarity of MVASI™ and Avastin® in non-squamous non-small cell lung cancer (NSCLC).1,*
IV = intravenous;
Q3W = once every 3 weeks.
†Patients remained on study for observation of disease progression and overall survival until the end of the study, withdrawal of consent, loss to follow-up, death, or until they received any other anticancer treatment such as maintenance therapy.1
*Patient population had either Stage 4 or recurrent metastatic non-squamous NSCLC with measurable disease according to RECIST v1.1, and initiated first-line carboplatin/paclitaxel.1
AMONG MVASI™ INDICATIONS, NSCLC REPRESENTS A SENSITIVE STUDY POPULATION FOR SHOWING CLINICAL SIMILARITY1,3
ECOG = Eastern Cooperative Oncology Group; PS = Performance Status.
Pregnancy warning
Most common adverse events
Indication-specific adverse events
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Prescribing Information for additional Important Safety Information.
MVASI™ Indications
MVASI™ is a vascular endothelial growth factor inhibitor indicated for the treatment of:
MVASI™, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer.
MVASI™, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab product-containing regimen.
Limitations of Use: MVASI™ is not indicated for adjuvant treatment of colon cancer.
MVASI™, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.
MVASI™ is indicated for the treatment of recurrent glioblastoma in adults.
MVASI™, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma.
MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
Avastin® (bevacizumab) is a registered trademark of Genentech USA, Inc.
MVASI™ Important Safety Information
References: 1. Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019;25:2088-2095. 2. MVASI™ (bevacizumab-awwb) Prescribing Information, Amgen. 3. US Food and Drug Administration. ODAC briefing document: ABP 215, a proposed biosimilar to US-Avastin. BLA 761028. July 13, 2017. 4. Data on file, Amgen; 2015 [CSR 20120265].